Adlon Therapeutics L.P. Joins the Prescription Drug Safety Network

National public-private coalition supports education around safe and responsible prescription medication use through digital education programs created by EVERFI

STAMFORD, Conn.–(BUSINESS WIRE)–Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., today announced it will join the Prescription Drug Safety Network (“the Network”) and will advance its commitment to education about the responsible use of prescription stimulants by extending EVERFI’s efforts to deliver the innovative, evidence-based prevention curriculum to high school students.

As part of its commitment to the Network, Adlon will provide support for EVERFI to deploy its school-based education in North Carolina and South Carolina as well as participate in Network initiatives. The Network, which was formed in 2017, currently includes 30 partner organizations representing health systems, pharmaceutical manufacturers, distributors, pharmacies, foundations, and state leaders, is committed to equipping students with the necessary skills to help them make safe and healthy decisions about prescription medications.

EVERFI’s prevention education curriculum provides students with basic information about three classes of prescription medicines (opioids, stimulants and depressants), including proper use and disposal, as well as interactive scenarios that help guide individual choices on potential situations involving misuse. EVERFI courses are aligned with the Centers for Disease Control and Prevention’s National Health Education Standards and state academic standards.

Over the past two years, with the support of all Network members, EVERFI has reached nearly 300,000 students in 2,950 high schools and 90 colleges and universities. As part of its first Prescription Drug Safety Impact Report, EVERFI reported an average knowledge gain of 49 percent in categories including identifying the signs of prescription drug misuse, confidence in their ability to step in to help someone who is misusing prescription drugs and understanding effective refusal skills.¹

“EVERFI believes in an upstream, primary prevention approach, which is designed to stop individuals from initiating prescription drug misuse or abuse before it begins. Research shows that prevention models can be effective in shaping behavior when they incorporate evidence-based approaches,” said Kimberley Timpf, senior director of impact and education, EVERFI. “Our ability to efficiently reach increasing numbers of students and measure the individual and community-level results of such programs would not be possible without a powerful network, and we greatly appreciate Adlon’s participation.”

In addition to Adlon’s involvement, Purdue Pharma has been a member of the Prescription Drug Safety Network since November 2017, with the goal of helping EVERFI reach 200 high schools in five states over three years. Since that time, EVERFI’s educational Prescription Drug Safety content has been accessed by almost 350 high schools in the five geographies sponsored by Purdue: California, Connecticut, Ohio, Tennessee, and West Virginia.

“EVERFI is at the forefront of prevention education. Their innovative digital programming addresses issues surrounding prescription drug safety and provides the tools to help young people understand the risks of misusing prescription medications,” said Craig Landau, MD, CEO, Purdue Pharma. “We’re proud to expand our support of EVERFI through Adlon Therapeutics, and believe this partnership is a strong example of our commitment to address prescription drug misuse, which includes opioids as well as other types of prescription medications.”

About EVERFI, Inc.

EVERFI, Inc. is the leading education technology company that provides learners of all ages education for the real world, through innovative and scalable digital learning. Founded in 2008, EVERFI has certified over 20 million learners in critical skill areas with more than 4,300 partners in all 50 U.S. states and Canada. EVERFI is an industry leader that builds Networks to tackle the toughest social issues, including the Campus Prevention Network, a coalition of higher education institutions committed to campus sexual assault and alcohol abuse prevention; and the Financial Capability Network, a coalition of industry leaders dedicated to improving financial outcomes for communities across the country.

About Adlon Therapeutics L.P.

Adlon Therapeutics L.P. is a biopharmaceutical company dedicated to developing and providing treatment options for Attention-Deficit/Hyperactivity Disorder (ADHD) and related disorders. Our initial focus is on adults and adolescents who have been diagnosed with ADHD. Adlon is a subsidiary of Purdue Pharma L.P. For more information, please visit www.adlontherapeutics.com.

Reference:

1. Prescription Drug Safety Network. Prescription Drug Safety Course. K-12 Impact Report 2017-2018. Retrieved from: https://everfi.com/networks/prescription-drug-safety-network/impact/. Accessed June 11, 2018.

Contacts

Media:

[email protected]